Elevated B-Type Natriuretic Peptide Level Expression Associated With Acute Myocardial Infarction Patients In Jammu Population (India)

Kapila Raina; Indu Priya; Chandni; A S Bhatia; H N Verma

doi:10.48165/

Authors

Kapila Raina Department of Biochemistry, Government Medical College, Jammu - 180 004, Jammu & Kashmir (India)
Indu Priya School of Biotechnology, University of Jammu, Jammu - 180 016, Jammu & Kashmir (India)
Chandni School of Biotechnology, University of Jammu, Jammu - 180 016, Jammu & Kashmir (India)
A S Bhatia Department of Biochemistry, Government Medical College, Jammu - 180 004, Jammu & Kashmir (India)
H N Verma Jaipur National University, Jaipur - 302 025, Rajasthan (India)

DOI:

https://doi.org/10.48165/

Keywords:

Acute myocardial infarction, B-type natriuretic peptide, enzyme immunoassay

Abstract

B-type natriuretic peptide (BNP) is a highly sensitive and specific indicator of the size of myocardial infarction, which can help in assessing the degree of cardiovascular risk. Elevated BNP levels in patients hospitalized for acute myocardial infarction (AMI) are associated with heart failure and mortality, and the measurements of BNP in a short-term period could be helpful to predict the future events. The role of short-term follow-up BNP level has not been established in the patients with AMI. This retrospective study was conducted on the patients admitted to the Government Medical College, Jammu (India). The analysis of blood EDTA sample was analysed for BNP and this test was performed by using a fully automated random access immunoassay analyser whose principle is based on micro-particle enzyme immunoassay (MEIA). The reference range of BNP is 0-100 pg mL-1. The study revealed a 90% BNP increase in AMI patients in comparison to the 10% increase in normal healthy ones. However, BNP showed elevated levels in healthy individuals suffering from renal insufficiency. The BNP was > 100 pg mL-1in the majority of AMI patients while in controls BNP is <100 pg mL-1.

Downloads

Download data is not yet available.

References

Cao, Z., Jia, Y. and Zhu, B. 2019. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. International Journal of Molecular Sciences, 20: 1820. [https://doi.org/10.3390/ijms20081820].

Durak-Nalbantić, A., Džubur, A., Dilić, M., Pozderac, Ž., Mujanović-Narančić, A., Kulić, M., Hodžić, E., Resić, N., Brdjanović, S. and Zvizdić, F. 2012. Brain natriuretic peptide release in acute myocardial infarction. Bosnian Journal of Basic Medical Sciences, 12(3): 164-168.

Fiore, M., Mitchell, J., Doan, T., Nelson, R., Winter, G., Grandone, C., Zeng, K., Haraden, R., Smith, J. and Harris, K. 1988. The Abbott IMx automated benchtop immunochemistry analyzer system. Clinical Chemistry, 34: 1726-1732.

Itakura, R., Inoue, Y., Ogawa, K., Nagoshi, T., Minai, K., Ogawa, T., Kawai, M. and Yoshimura, M. 2020. A highly-sensitized response of B-type natriuretic peptide to cardiac ischaemia quantified by intracoronary pressure measurements. Scientific Reports, 10: 1-11.

Januzzi, J.L. 2020. Troponin and BNP use in COVID-19. Cardiology Magazine, 18 March, 2020. [https://www.acc.org/latest-in-cardiology//articles/2020/03/18/25/troponin-and-bnp-use-in- covid19]. Khan, S.Q., Dhillon, O., Kelly, D., Squire, I.B., Struck, J., Quinn, P., Morgenthaler, N.G., Bergmann, A., Davies, J.E. and Ng, L.L. 2008. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: Comparison with plasma midregional

Kapila Raina et al.

pro-atrial natriuretic peptide: The LAMP (Leicester acute myocardial infarction peptide) study. Journal of the American College of Cardiology, 51: 1857-1864.

Kotecha, D., Flather, M.D., Atar, D., Collins, P., Pepper, J., Jenkins, E., Reid, C.M. and Eccleston, D. 2019. B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. BMC Medicine, 17: 1-11.

Kumar, V., Brent, J.R., Shorie, M., Kaur, H., Chadha, G., Thomas, A.G., Lewis, E.A., Rooney, A.P., Nguyen, L., Zhong, X.L. and Burke, M.G. 2016. Nanostructured aptamer-functionalized black phosphorus sensing platform for label-free detection of myoglobin, a cardiovascular disease biomarker. ACS Applied Materials & Interfaces, 8: 22860-22868.

Lee, J.W., Choi, E., Khanam, S.S., Son, J.W., Youn, Y.J., Ahn, M.S., Ahn, S.G., Kim, J.Y., Lee, S.H., Yoon, J. and Yoo, B.S. 2019. Prognostic value of short-term follow-up B-type natriuretic peptide levels after hospital discharge in patients with acute myocardial infarction. International Journal of Cardiology, 289: 19-23.

Morrow, D.A., de Lemos, J.A., Sabatine, M.S., Murphy, S.A., Demopoulos, L.A., DiBattiste, P.M., McCabe, C.H., Gibson, C.M., Cannon, C.P. and Braunwald, E. 2003. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non–ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. Journal of the American College of Cardiology, 41: 1264-1272.

Reddy, K., Khaliq, A. and Henning, R.J. 2015. Recent advances in the diagnosis and treatment of acute myocardial infarction. World Journal of Cardiology, 7: 243-276.

Reesukumal, K., Pratumvinit, B., Maneesai, A., Tresukosol, D. and Opartkiattikul, N. 2009. An evaluation of B-type natriuretic peptide in addition to myoglobin, creatine kinase-MB, and troponin I on the emergency department patients with acute myocardial infarction. Siriraj Medical Journal, 61: 126-129.

Savarese, G. and Lund, L.H. 2017. Global public health burden of heart failure. Cardiac Failure Review, 3: 7-11.

Yildirim, T., Yildirim, S. E., Aktoz, M. And Altun, A. 2018. Brain natriuretic peptide levels in acute inferior myocardial infarction. Journal of Clinical Medicine Research, 10: 254-259. Zandijk, A.J., van Norel, M.R., Julius, F.E., Sepehrvand, N., Pannu, N., McAlister, F.A., Voors, A.A. and Ezekowitz, J.A. 2021. Chloride in heart failure: The neglected electrolyte. Heart Failure, 9: 904-915.